

RISANKIZUMAB LEVELS ARE SIGNIFICANTLY CORRELATED AND PREDICTIVE OF BIOMARKER REMISSION IN CROHN'S DISEASE

Mathilde BARRAU

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

Risankizumab trough levels correlate with clinical remission in Crohn disease patients, with levels above 10.6 µg/mL associated with better outcomes in a 26-patient study.

KEY POINTS

- Mean risankizumab levels during maintenance were significantly higher in clinical remission versus absence of clinical remission (22.5 versus 6.1 µg/mL, $p < 0.0001$)
- Clinical remission rates increased from 4% at trough levels ≤ 4.9 µg/mL (quartile 1) to 88% at levels > 19.6 µg/mL (quartile 4)
- Higher risankizumab trough level quartiles were associated with greater rates of clinical response ($p = 0.001$)
- The study included 26 Crohn disease patients on standard risankizumab regimen (600mg IV induction then 360mg subcutaneous every 8 weeks) with 97 maintenance samples analyzed
- The authors conclude that trough concentration above 10.6 µg/mL should be recommended in clinical practice

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/969adfea-743b-11ee-9c75-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.